Drawing for DARNITSA GROUP

USPTO serial 79276074

DARNITSA GROUP

Reviewed by CopyMark Law Group

Reg. 6235826Status 700Renewal
Filing date
Status date
Registration date
Jan 5, 2021
Examiner
MAZZELLA,BRANDY BARRETT
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with DARNITSA GROUP?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*

Plus Government fees of $325

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kenneth Motolenich-Salas

Kenneth Motolenich-Salas Hickman Becker Bingham Ledesma LLP99 Almaden Boulevard, Suite 600San Jose, CA 95113UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Antiseptics; vaccines; veterinary preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vitamin preparations; disinfectants; diagnostic preparations for veterinary purposes; diagnostic preparations for medical purposes; dietetic beverages adapted for medical purposes; Dietetic foods and beverages adapted for medical use; dietetic foods adapted for medical purposes; plant extracts for pharmaceutical purposes; herbal extracts for medical purposes; Capsules sold empty for pharmaceuticals; medicinal preparations for human purposes for medicines for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Drugs for medical purposes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Medicinal drinks; medicinal oils; medicated toiletry preparations; medicated shampoos; ointments for pharmaceutical purposes for ointments for pharmaceutical purposes, namely, medicated ointments for treating dermatological conditions and antibiotic ointments; teeth filling material; medicinal alcohol; food supplements; medical dressings; nutritional supplements; Pre-filled syringes containing pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Air purifying preparations; food for babies; protein dietary supplements; Tissues impregnated with pharmaceutical lotions for treating dermatological conditions; Alcohol for pharmaceutical purposes; stem cells for medical purposes; transplants, namely, surgical implants comprising living tissue used in transplant operations; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; ferments for pharmaceutical purposes; phytotherapy preparations for medical purposes; chemico-pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Chemical preparations for medical purposes for the diagnosis of pregnancy; Chemical preparations for pharmaceutical purposes for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Chemical reagents for medical or veterinary purposes; surgical glues; surgical dressings; candy, medicated; candy for medical purposes; sanitary preparations for medical purposes; plasters for medical purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 5, 2026REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Feb 7, 2025ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Jan 4, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Aug 3, 2023EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Aug 3, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 3, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 3, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 30, 2021FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 9, 2021XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Apr 9, 2021XXCRGENERIC MADRID TRANSACTION CREATED—
Apr 5, 2021FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jan 5, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 18, 2020NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 6, 2020GPNXNOTIFICATION PROCESSED BY IB—
Nov 13, 2020OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Oct 20, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 20, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 30, 2020OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Sep 30, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 17, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 3, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 3, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 3, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 3, 2020ALIEASSIGNED TO LIE—
Aug 13, 2020PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Aug 12, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 12, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 28, 2020RFNTREFUSAL PROCESSED BY IB—
Feb 12, 2020RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 12, 2020RFRRREFUSAL PROCESSED BY MPU—
Jan 18, 2020RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 17, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 14, 2020MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 10, 2020DOCKASSIGNED TO EXAMINER—
Jan 10, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 9, 2020REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance